|
#91
06.02.2009, 12:40
|
|||
|
|||
|
Цитата:
Вот Вы писали: Цитата:
Но метод, конечно, может использоваться. Что касается CT Angiogram, то ясность о значении этого метода вроде потихоньку наступает. 
|
|
#92
06.02.2009, 13:32
|
||||
|
||||
|
Видел несколько МРТ (объемная визуализация сосудов головного мозга) - некоторые сосуды просто не видны, не думаю что это может заменить обычную ангиографию.
|
|
#93
06.02.2009, 17:43
|
||||
|
||||
|
Цитата:
|
|
#94
07.02.2009, 10:28
|
||||
|
||||
|
АААААААААААА!!!!!!!!!!!!!!!!!!!
Найдена панацея! Наслаждайтесь: Цитата:
|
|
#95
07.02.2009, 11:38
|
||||
|
||||
|
Цитата:
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent)Study. A Prospective, Randomized Control Trial (Circulation February 17, 2009) [Ссылки доступны только зарегистрированным пользователям ]
|
|
#97
14.02.2009, 09:54
|
||||
|
||||
|
Цитата:
|
|
#99
19.02.2009, 21:26
|
|||
|
|||
|
SYNTAX
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease Patrick W. Serruys, M.D., Ph.D., Marie-Claude Morice, M.D., A. Pieter Kappetein, M.D., Ph.D., Antonio Colombo, M.D., David R. Holmes, M.D., Michael J. Mack, M.D., Elisabeth Ståhle, M.D., Ted E. Feldman, M.D., Marcel van den Brand, M.D., Eric J. Bass, B.A., Nic Van Dyck, R.N., Katrin Leadley, M.D., Keith D. Dawkins, M.D., Friedrich W. Mohr, M.D., Ph.D., for the SYNTAX InvestigatorsBackground Percutaneous coronary intervention (PCI) involving drug-eluting stents is increasingly used to treat complex coronary artery disease, although coronary-artery bypass grafting (CABG) has been the treatment of choice historically. Our trial compared PCI and CABG for treating patients with previously untreated three-vessel or left main coronary artery disease (or both). Methods We randomly assigned 1800 patients with three-vessel or left main coronary artery disease to undergo CABG or PCI (in a 1:1 ratio). For all these patients, the local cardiac surgeon and interventional cardiologist determined that equivalent anatomical revascularization could be achieved with either treatment. A noninferiority comparison of the two groups was performed for the primary end point — a major adverse cardiac or cerebrovascular event (i.e., death from any cause, stroke, myocardial infarction, or repeat revascularization) during the 12-month period after randomization. Patients for whom only one of the two treatment options would be beneficial, because of anatomical features or clinical conditions, were entered into a parallel, nested CABG or PCI registry. Results Most of the preoperative characteristics were similar in the two groups. Rates of major adverse cardiac or cerebrovascular events at 12 months were significantly higher in the PCI group (17.8%, vs. 12.4% for CABG; P=0.002), in large part because of an increased rate of repeat revascularization (13.5% vs. 5.9%, P<0.001); as a result, the criterion for noninferiority was not met. At 12 months, the rates of death and myocardial infarction were similar between the two groups; stroke was significantly more likely to occur with CABG (2.2%, vs. 0.6% with PCI; P=0.003). Conclusions CABG remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year. (ClinicalTrials.gov number, NCT00114972 [Ссылки доступны только зарегистрированным пользователям ] .)http://content.nejm.org/cgi/content/full/NEJMoa0804626
|
|
#100
19.02.2009, 22:18
|
||||
|
||||
|
Реваскуляризация при стабильной стенокардии улучшает выживаемость
[Ссылки доступны только зарегистрированным пользователям ]
|
|
#101
22.02.2009, 17:35
|
|||
|
|||
|
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction
J. J. Smit*, W. van Oeveren†, J. P. Ottervanger*, R. J. Slingerland‡, J. A. Remijn*‡, F. Zijlstra¶ and A. W. J. van ‘t Hof Background Iron and (stainless) steel are potent platelet aggregation activators, and may be involved in stent thrombosis, a serious complication after intracoronary stenting. Current platelet function tests are suboptimal,because of inappropriate agonists and/or lack of reproducibility. We tested the feasibility and reproducibility of a novel platelet function test using stainless steel as an agonist and compared it with other platelet function tests. Materials and methods In 111 patients with acute ST segment elevation myocardial infarction (STEMI), duplo measurements of iron (Fe)-induced platelet aggregation (FIPA) were performed after clopidogrel, acetylsalicylic acid and/or tirofiban treatment. Within 1 h, citrated blood samples drawn from the femoral sheath before primary percutaneous coronary intervention were added to 100 mg of low carbon steel and after 5 s mixing with vortex, the samples were incubated for 15 min. The ratio between the non-aggregated platelets in the agonist sample and platelets in a reference sample was calculated as the platelet aggregation inhibition. Results FIPA measurement was highly reproducible (correlation coefficient (R) = 0·942, P < 0·001 between duplo samples). FIPA correlated well with adenosine diphosphate-induced platelet aggregation (R = 0·83, P < 0·001) but weakly with platelet function analyser-100 bleeding time (R = 0·56, P < 0·001). FIPA could be measured in patients in which platelet aggregation could not be measured by platelet function analyser-100 or afteradenosine diphosphate. Conclusion This study showed good reproducibility of a novel platelet function test using stainless steel as an agonist and showed correlation with validated platelet function tests. We found that the novel platelet functiontest is a suitable test for measurement of platelet aggregation inhibition in patients undergoing stenting for STEMI, even when they are taking multiple antiplatelet regimens. Eur J Clin Invest 2009; 39 (2): 103–109 [Ссылки доступны только зарегистрированным пользователям ]
|
|
#102
23.02.2009, 15:47
|
||||
|
||||
|
Предлагаю последний гайд АСС/АНА по стандартизации и интерпретации ЭКГ (было 2 части, теперь- 6), в списке первый
[Ссылки доступны только зарегистрированным пользователям ]
|
|
#104
25.02.2009, 22:21
|
|||
|
|||
|
Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines
Pierluigi Tricoci, MD, MHS, PhD; Joseph M. Allen, MA; Judith M. Kramer, MD, MS; Robert M. Califf, MD; Sidney C. Smith Jr, MD JAMA. 2009;301(8):831-841. [Ссылки доступны только зарегистрированным пользователям ] Practice guidelines are actually expert consensus reports. Возможно, заслуживает обсуждения  .
|
Линейный вид
